A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin detemir, Insulin NPH, Diet/exercise, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.